Sotiracib is an acrylamide derived KRAS inhibitor developed by Anjin Corporation and currently undergoing clinical trials for the treatment of solid tumors with KRAS G12C mutations. This mutation accounts for over 50% of all KRAS mutations. It is the first experimental KRAS inhibitor. The drug [MRTX849] is currently under development and has the same goals